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Abstract
Background: Irritable bowel syndrome (IBS) affects 10–15% of adults in the US, and is associated with significant
impairment in health-related quality of life (HRQoL); however, information specific to the diarrhea subtype (IBS-D) is
lacking. We assessed the impact of IBS-D on HRQoL, work productivity, and daily activities, and the associated
indirect costs, among a sample of the US population.
Methods: Respondents (≥18 years) from the 2012 US National Health and Wellness Survey who reported an IBS-D
diagnosis by a physician or symptoms consistent with Rome II criteria for IBS-D were identified as having IBS-D.
Controls included respondents without IBS-D or inflammatory bowel disease. HRQoL was assessed via the Short
Form 36 Health Survey version 2 questionnaire and summarized into Mental and Physical Component Summary
(MCS; PCS) scores and a Short Form-6 dimension (SF-6D) utility score. Work and activity impairment were assessed
via the Work Productivity and Activity Impairment Questionnaire: General Health version (WPAI:GH), which measures
absenteeism, presenteeism, overall work productivity loss, and daily activity impairment. Indirect costs were
calculated using unit cost data from the Bureau of Labor Statistics and variables from the WPAI:GH. Generalized
linear models were used to examine differences in health outcomes between respondents with IBS-D and controls,
controlling for demographic and health characteristics.
Results: In total, 66,491 respondents (1102 IBS-D; 65,389 controls) were analyzed. Mean age was 48.7 years; 50%
were female. Compared with controls, the IBS-D cohort reported significantly lower HRQoL (mean MCS: 45.16 vs. 49.
48; p < 0.001; mean PCS: 47.29 vs. 50.67; p < 0.001; mean SF-6D: 0.677 vs. 0.741; p < 0.001) and greater absenteeism
(5.1% vs. 2.9%; p = 0.004), presenteeism (17.9% vs. 11.3%; p < 0.001), overall work productivity loss (20.7% vs. 13.2%;
p < 0.001), and activity impairment (29.6% vs. 18.9%; p < 0.001). Respondents with IBS-D also incurred an estimated
$2486 more in indirect costs ($7008 vs. $4522; p < 0.001).
Conclusions: Compared with controls, IBS-D is associated with significantly lower HRQoL, greater impairments in
work and daily activities, and higher indirect costs, imposing a substantial burden on patients and employers.
These findings suggest a significant unmet need exists for effective IBS-D treatments.
Keywords: Irritable bowel syndrome with diarrhea, IBS-D, Health-related quality of life, HRQoL, Work productivity
impairment, Activity impairment, Indirect costs, National Health and Wellness Survey
* Correspondence: Jessica.Abel@allergan.com
1Allergan plc, Jersey City, NJ, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Buono et al. Health and Quality of Life Outcomes  (2017) 15:35 
DOI 10.1186/s12955-017-0611-2
Background
Irritable bowel syndrome (IBS) is a chronic functional
gastrointestinal disorder characterized by abdominal
pain or discomfort associated with altered bowel habits,
in the absence of discernable organic disease such as
microscopic colitis and inflammatory bowel disease
(IBD) [1, 2]. IBS affects 10–15% of adults in the US, and
is a common diagnosis in both gastroenterology and pri-
mary care practices [3]. IBS is classified into subtypes
based on predominant stool pattern, including IBS with
diarrhea (IBS-D), IBS with constipation (IBS-C), and IBS
with mixed bowel patterns of constipation and diarrhea
[2]. IBS-D is estimated to account for approximately
one-third of IBS cases [4].
As the symptom profile and management strategies
for each IBS subtype differ, it is important to understand
the burden of illness associated with each subtype. While
prior studies have assessed the impact of IBS-C on
health-related quality of life (HRQoL) and work and ac-
tivity impairment [5, 6], information specific to the bur-
den of IBS-D is limited [7].
Among IBS overall, the symptom burden experienced
by patients is associated with significant impairments in
HRQoL [3, 7, 8]. In a systematic review, patients with
IBS had significantly lower scores compared with con-
trols across every domain of the Short Form 36 Health
Survey (SF-36), a measure for assessing HRQoL – in-
cluding both physical and emotional role functioning –
as well as mental health [7]. In a further study, impair-
ments in HRQoL experienced by IBS patients were com-
parable to or greater than HRQoL impairments seen
among patients with other chronic diseases, with IBS pa-
tients reporting lower HRQoL based on several domains
of the SF-36, including bodily pain, social functioning,
and mental health, in comparison with patients with
asthma, gastroesophageal reflux disease (GERD), and
migraine [9]. For IBS-D specifically, the burden of symp-
toms, including abdominal pain, loose and watery stools,
cramping, and bloating, can significantly impact patients
physically, emotionally, and socially. In a recent survey
of 1000 IBS-D patients in the US, over half of IBS-D pa-
tients reported their symptoms were extremely or very
bothersome [10].
While information specific to IBS-D is limited, IBS in
general is also associated with significant impairments in
work productivity. In a 2015 survey conducted by the
American Gastroenterological Association, IBS patients
reported that their symptoms interfered with work prod-
uctivity an average of 9 days per month and that they
missed an average of 2 days of work per month [10]. In-
direct costs (e.g. loss of work and reduced productivity)
of IBS have been estimated at up to $20 billion annually
in the US, with an estimated annual cost per patient of
$9933 (in 2012 US dollars) [3, 7].
Given that data specific to the burden associated with
IBS-D are limited, the objective of this study was to quan-
tify the burden of disease among individuals with IBS-D
relative to those without IBS-D, with regard to HRQoL,
work productivity loss and daily activity impairment, and




This study utilized data from the 2012 US National Health
and Wellness Survey (NHWS), a self-administered, internet-
based general health questionnaire, from a sample of adults
in the US (aged ≥18 years). Adults were identified for inclu-
sion in the survey through a web-based opt-in consumer
panel of pre-recruited individuals who consented to partici-
pate in research. Stratified random sampling (with strati-
fication by gender and age) was used to ensure the
demographic composition of the survey population was
representative of the US adult population based on data
from the US Census.
Sample population
The initial study sample included all respondents who
completed the 2012 NHWS (Fig. 1). Respondents with
IBS-D were classified into two categories: 1) “diagnosed”
IBS-D, if they self-reported a diagnosis of IBS by a phys-
ician and reported diarrhea as the predominant bowel
symptom; or 2) “undiagnosed IBS-D”, if they reported
symptoms consistent with the Rome II criteria for IBS-D
Fig. 1 Respondent identification.
aDefined as respondents who self-reported a diagnosis of IBS-D by a
physician and reported diarrhea as the predominant bowel symptom.
bDefined as respondents who reported symptoms consistent with the
Rome II criteria for an IBS-D diagnosis but did not self-report a diagnosis
of IBS-D by a physician.
Abbreviations: IBS-D irritable bowel syndrome with diarrhea
Buono et al. Health and Quality of Life Outcomes  (2017) 15:35 Page 2 of 8
but did not self-report a diagnosis of IBS-D by a
physician. Controls included respondents who did not
self-report experiencing IBS symptoms (any subtype) or
subsequent diagnoses, did not meet symptom criteria for
IBS according to the Rome II criteria, and did not self-
report experiencing IBD or subsequent diagnoses.
Study design
This study was an analysis of cross-sectional survey data
assessing HRQoL and work productivity and daily activity
impairment among respondents with IBS-D relative to
controls. HRQoL was evaluated based on the Medical Out-
comes SF-36 version 2 (SF-36v2) [11], which includes a
Physical Component Summary (PCS) score and a Mental
Component Summary (MCS) score (range: 0–100). Higher
scores indicate better quality of life. Health utility scores
were derived from the SF-36v2 by calculating the Short
Form-6 dimension (SF-6D) score, a health state classification
measure ranging from 0.0 (death) to 1.0 (best health state).
Work productivity and activity impairment were assessed
based on the Work Productivity and Activity Impairment
Questionnaire: General Health version (WPAI:GH) [12].
The WPAI:GH consists of six items measuring four
domains: 1) absenteeism (percentage of work time missed
due to health problems in the past 7 days, calculated as:
[hours missed due to health problems/(hours missed due to
health problems + hours worked)] x 100); 2) presenteeism
(percentage of impairment experienced at work due to
health problems in the past 7 days, calculated as: [degree
health affected productivity while working/10] x 100); 3)
overall work productivity loss (absenteeism plus presentee-
ism, calculated as: [absenteeism + (hours worked x present-
eeism)] x 100); and 4) daily activity impairment (percentage
of impairment in daily activities due to health problems in
the past 7 days, calculated as: [degree health affected daily
activities/10] x 100). Only respondents who reported being
employed (full or part time) provided data for absenteeism,
presenteeism, and overall work productivity loss; all respon-
dents provided data for daily activity impairment. All
domain scores are expressed as percentages, with higher
percentages indicating greater work productivity loss and
activity impairment. Days of work missed annually (for
employed participants only) were calculated using reported
work hours missed based on the WPAI:GH, assuming a
40-hour work week and 50 weeks worked annually.
Estimated annual indirect costs were calculated by in-
tegrating data from the Bureau of Labor Statistics and
the WPAI:GH, with 2012 median weekly wages by age
and sex obtained from the Bureau of Labor Statistics ap-
plied as unit costs to work productivity variables (absen-
teeism and presenteeism) from the WPAI:GH. The
number of hours missed due to absenteeism and pres-
enteeism were calculated for each respondent and multi-
plied by their associated estimated hourly wage, based
on age and gender. These figures were annualized by
multiplying by 50 work weeks in a year, and combined
to estimate the total indirect costs. Costs are presented
in 2012 US dollars.
Statistical analysis
Differences in demographic and health characteristics
between diagnosed respondents with IBS-D, undiagnosed
respondents with IBS-D, and controls were examined utiliz-
ing one-way analysis of variance (for continuous variables)
and Chi-square tests (for categorical variables). When
comparing more than two groups, appropriate pairwise
comparisons were used. For analysis of differences in
HRQoL, work productivity and activity impairment, and in-
direct costs, diagnosed and undiagnosed respondents with
IBS-D were combined into a single category of “IBS-D”.
Generalized linear models were used to assess differ-
ences in HRQoL, work productivity, and daily activity
impairment between respondents with IBS-D (undiag-
nosed and diagnosed combined) and controls, control-
ling for all demographic and health characteristics
identified a priori, including age, gender, ethnicity, in-
come, education, body mass index category, smoking
status, alcohol use, exercise activity, and Charlson Co-
morbidity Index (CCI). Estimated means and standard
errors are reported. For all measures, differences were
considered significant at p < 0.05.
Results
Demographics and health characteristics
The sample population included a total of 66,491 respon-
dents: 1102 with IBS-D (842 diagnosed, 260 undiagnosed)
and 65,389 controls (Fig. 1). In the overall sample, mean
age was 48.7 years, 50% were female, and 54% were
employed (Table 1). Respondents with IBS-D were more
likely to be female (diagnosed: 60.6%; undiagnosed: 65.0%;
controls: 50.0%; p < 0.001) and had a higher CCI score
than controls (diagnosed: 0.72; undiagnosed: 0.75; con-
trols: 0.41; p < 0.001).
Among respondents who reported a diagnosis of IBS-D,
the majority were diagnosed by a primary care physician
(51.5%) or a gastroenterologist (40.0%), with the remainder
reporting being diagnosed by a nurse practitioner/physician
assistant (2.9%), obstetrician/gynecologist (1.5%), or other
practitioner (4.1%). The average time since diagnosis of
IBS-D was 11 years. Of diagnosed IBS-D respondents,
28.8% reported current use of prescription medication, and
33.8% reported the use of an over-the-counter (OTC)
medication. Dicyclomine hydrochloride was the most
commonly reported prescription medicine (16.7%), while
loperamide was the most commonly reported OTC medi-
cation (43.6%). Among the diagnosed respondents, 48.0%
reported having symptoms at least 2 to 3 times per week,
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and 55.8% considered their symptoms to be bothersome to
extremely bothersome (Table 2).
Health-related quality of life
As minimal differences in demographics (and outcomes,
including HRQoL and work productivity and activity im-
pairment [data not shown]) were observed between the
diagnosed and undiagnosed IBS-D cohorts, these two
groups were combined into a single category of “IBS-D”
for all subsequent analyses. Respondents with IBS-D re-
ported significantly lower HRQoL versus controls. Mean
MCS (45.16 vs. 49.48; p < 0.001) and PCS (47.29 vs.
50.67; p < 0.001) scores were significantly lower for indi-
viduals with IBS-D than for controls, after controlling
for demographic and health characteristics (Table 3).
Mean SF-6D scores for respondents with IBS-D were
also significantly lower than in the control group, with a
mean difference of 0.064 (0.677 vs. 0741; p < 0.001) after
adjusting for covariates (Table 3). For the eight subscales
that make up the SF-36v2, respondents with IBS-D had
significantly lower scores than controls in all domains
(p < 0.001 vs. controls for all domains) [Table 3].
Work productivity and activity impairment
Compared with controls, respondents with IBS-D
missed significantly more work (absenteeism 5.1% vs.
2.9%; p = 0.004), experienced higher levels of presentee-
ism while at work (17.9% vs. 11.3%; p < 0.001), and had
greater overall work productivity loss (20.7% vs. 13.2%;
p < 0.001) and higher daily activity impairment (29.6%
vs. 18.9%; p < 0.001) [Fig. 2]. Individuals with IBS-D also
missed significantly more work days annually compared
with controls, with a mean difference of 3.9 days lost per
year (10.1 vs. 6.2; p = 0.031).










Age, mean (SD) 48.72 (16.61) 50.39 (15.79)a 43.05 (14.40)b 48.72 (16.62)c <0.001
Charlson Comorbidity Index, mean (SD) 0.42 (0.99) 0.72 (1.23)a 0.75 (1.50)a 0.41 (0.98)b <0.001
Female, n (%) 33377 (50.2) 510 (60.6)a 169 (65.0)a 32698 (50.0)b
Race/ethnicity, n (%) <0.001
Non-Hispanic White 47700 (71.7) 712 (84.6)a 180 (69.2)b 46808 (71.6)b
Non-Hispanic Black 7857 (11.8) 31 (3.7)a 28 (10.8)b 7798 (11.9)b
Hispanic 5603 (8.4) 49 (5.8)a 27 (10.4)b 5527 (8.5)b
Other ethnicity 5331 (8.0) 50 (5.9)a 25 (9.6)b 5256 (8.0)b
Education, n (%) 0.069
< 4-year degree 39657 (59.6) 496 (58.9)a 173 (66.5)b 38988 (59.6)a
≥ 4-year degree 26834 (40.4) 346 (41.1)a 87 (33.5)b 26401 (40.4)a
Annual household income, n (%) 0.008
< $25 k 12750 (19.2) 161 (19.1)a 65 (25.0)b 12524 (19.2)a
$25–50 k 17775 (26.7) 215 (25.5)a 80 (30.8)a 17480 (26.7)a
$50–75 k 13037 (19.6) 189 (22.4)a 54 (20.8)a,b 12794 (19.6)b
≥ $75 k 17369 (26.1) 214 (25.4)a 46 (17.7)b 17109 (26.2)a
Declined to answer 5560 (8.4) 63 (7.5)a 15 (5.8)a 5482 (8.4)a
Labor force participation, n (%) 0.424
Yes 35636 (53.6) 433 (51.4)a 142 (54.6)a 35061 (53.6)a
No 30855 (46.4) 409 (48.6)a 118 (45.4)a 30328 (46.4)a
Body mass index, n (%) <0.001
Underweight (<18.5) 1231 (1.9) 11 (1.3)a 3 (1.2)a 1217 (1.9)a
Normal weight (18.5–24.99) 20894 (31.4) 228 (27.1)a 76 (29.2)a,b 20590 (31.5)b
Overweight (25–29.99) 21347 (32.1) 243 (28.9)a 68 (26.2)a 21036 (32.2)b
Obese (≥30) 21265 (32.0) 341 (40.5)a 111 (42.7)a 20813 (31.8)b
Unknown 1754 (2.6) 19 (2.3)a 2 (0.8)a 1733 (2.7)a
For pairwise comparisons, values in the same row not sharing the same subscript letter (a, b, or c) are significantly different at p < 0.05
Abbreviations: IBS-D irritable bowel syndrome with diarrhea, SD standard deviation
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Indirect costs
IBS-D was associated with significantly increased costs result-
ing from both presenteeism ($5402 vs. $3518; p < 0.001) and
absenteeism ($1642 vs. $977; p < 0.05). Based on overall work
productivity loss, estimated indirect costs were $2486 higher
per employed respondent per year for those with IBS-D com-
pared with controls ($7008 vs. $4522; p < 0.001) [Fig. 3].
Discussion
Previous research has shown the significant impact of
IBS on HRQoL, work productivity, and daily activities
[3, 7, 8, 13]. To our knowledge, this study is the first to
demonstrate the significant burden of illness specific to
the IBS-D subtype with regard to impairments in
HRQoL, work and daily activities, and indirect costs,
highlighting the substantial burden of IBS-D for both
patients and employers.
Respondents with IBS-D in this population reported
significantly lower HRQoL, including lower levels of
mental and physical well-being compared with controls.
Additionally, mean MCS (45.16) and PCS (47.29) scores
for individuals with IBS-D were lower than the US mean
norm of 50 and a standard deviation of 10 for the SF-
36v2, whereas controls without IBS-D had mean scores
closer to the US mean norm (MCS 49.48, PCS 50.67).
The lowest scores and greatest differences from controls
were seen on the general health, vitality, bodily pain,
mental health, role limitations due to emotional prob-
lems, and social functioning scales, suggesting that the
HRQoL burden of IBS-D is largely attributable to the
mental impact of the disorder, rather than to physical
limitations. These findings are in line with the previously
reported impact of IBS on patients’ emotional state, in-
cluding increased symptoms of anxiety and depression
[14], which have been reported across IBS subtypes [15–
17]. These reductions in HRQoL also underscore the
negative impact IBS-D symptoms have on patients’ lives
and a continued unmet need for therapeutic options to
effectively treat and manage the multiple symptoms of
IBS-D. The reductions in HRQoL observed among
Table 2 Frequency, bothersomeness, and severity of symptoms
among respondents with IBS-D (diagnosed and undiagnosed)
Response Respondents
n = 875a






4–6 times a week 114 (13.0)
2–3 times a week 186 (21.3)
Once a week 112 (12.8)
2–3 times a month 204 (23.3)
Once a month or less often 139 (15.9)
Bothersomeness of IBS
symptoms, n (%)
Not at all bothersome 51 (5.8)
Somewhat bothersome 335 (38.3)
Bothersome 241 (27.5)
Very bothersome 162 (18.5)
Extremely bothersome 86 (9.8)
aNot all IBS-D respondents provided a response
Abbreviations: IBS irritable bowel syndrome, IBS-D irritable bowel syndrome
with diarrhea
Table 3 SF-36v2 and SF-6D scores among respondents with IBS-D (diagnosed and undiagnosed) and controls
Score, mean (SE) IBS-D Controls p-valuea
n = 1102 n = 65,389
SF-36v2 summary scores
MCS 45.16 (0.29) 49.48 (0.04) <0.001
PCS 47.29 (0.25) 50.67 (0.03) <0.001
SF-36v2 subscales
Bodily pain 45.66 (0.28) 50.20 (0.04) <0.001
General health 45.88 (0.27) 50.89 (0.04) <0.001
Mental health 45.32 (0.30) 49.40 (0.04) <0.001
Physical functioning 47.76 (0.27) 50.09 (0.04) <0.001
Role limitations due to emotional problems 46.11 (0.30) 49.47 (0.04) <0.001
Role limitations due to physical health 47.01 (0.27) 50.25 (0.03) <0.001
Social functioning 45.35 (0.28) 49.75 (0.04) <0.001
Vitality 45.74 (0.28) 50.65 (0.04) <0.001
SF-6D score 0.667 (0.004) 0.741 (0.000) <0.001
aAnalyses adjusted for age, gender, ethnicity, income, education, body mass index, smoking status, alcohol use, exercise activity, and Charlson Comorbidity Index
Abbreviations: IBS-D irritable bowel syndrome with diarrhea, MCS Mental Component Summary, PCS Physical Component Summary, SE standard error, SF-36v2
Short Form 36 Health Survey version 2, SF-6D Short Form 6-dimension
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individuals with IBS-D in this study are comparable to
reductions observed among patients with other chronic
conditions with burdensome symptoms, such as asthma,
GERD, and migraine [9, 18].
Employed respondents with IBS-D in this population
reported significantly higher levels of absenteeism, pres-
enteeism, and overall work productivity loss compared
with controls, with 3.9 more missed work days per year
for those with IBS-D. Respondents with IBS-D also re-
ported greater impairments in daily activities (29.6%)
compared with both controls (18.9%) and the general
US population (average score of 22.1%) [19]. These
impairments in work productivity and daily activities
are comparable to those reported for other chronic dis-
orders, such as among patients with controlled asthma
[20].
Lost time from work translated into indirect costs of
$2486 more per employed respondent with IBS-D per
year in this population, with approximately three-quarters
of the total annual indirect costs for respondents with
IBS-D attributable to presenteeism. This suggests patients
may be impacted by the chronic symptoms associated
with IBS-D in a manner that impairs their ability to main-
tain high levels of productivity in the workforce. This
Fig. 2 Work productivity and activity impairment among respondents with IBS-D (diagnosed and undiagnosed) and controlsa.
aAnalyses adjusted for age, gender, ethnicity, income, education, body mass index, smoking status, alcohol use, exercise activity, and Charlson
Comorbidity Index.
bIncludes diagnosed and undiagnosed respondents.
cIncludes employed respondents only (n = 557 for respondents with IBS-D, n = 33,414 for controls).
Abbreviations: IBS-D irritable bowel syndrome with diarrhea, WPAI:GH Work Productivity and Activity Impairment: General Health version
Fig. 3 Annual indirect costs among respondents with IBS-D (diagnosed and undiagnosed) and controlsa.
aIncludes employed respondents only (n= 557 for respondents with IBS-D, n= 33,414 for controls).
*Difference significant at p< 0.05, adjusted for age, gender, income, education, body mass index, smoking status, alcohol use, exercise activity, and Charlson
Comorbidity Index.
Abbreviations: IBS-D irritable bowel syndrome with diarrhea, USD US dollars
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productivity loss and activity impairment further empha-
sizes the significant impact of IBS-D symptoms on both
patients and the wider society, outside of any direct med-
ical costs that may also be incurred due to the disorder.
Limitations
The results of this study should be interpreted in light of
certain limitations. As with any survey, the data are self-
reported and cannot be independently verified by re-
spondents’ medical charts or other objective data. The
data are also cross-sectional in nature and therefore do
not allow for causal inferences to be made. The data ex-
trapolated for the analysis of indirect costs represent the
most up-to-date unit cost information available at the
time of the study; however, this is unlikely to affect
relative comparisons between groups and may even re-
sult in a more conservative estimate of the indirect costs.
Finally, although a number of respondent demographic
and health characteristics were controlled for, there may
be additional variables that were not controlled for,
which could have affected the results.
Conclusions
This study highlights the substantial disease burden
among patients living with IBS-D, a chronic functional
gastrointestinal disorder characterized by bothersome
bowel and abdominal symptoms. Compared with con-
trols, respondents with IBS-D reported significantly
greater reductions in HRQoL, greater impairments in
work productivity and daily activities, and higher rates of
absenteeism and presenteeism that translate into a sig-
nificant burden to employers in terms of indirect costs.
These findings suggest a significant unmet need exists
for therapies to effectively treat the symptoms of IBS-D
and alleviate the considerable societal and patient bur-
den associated with this condition.
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